Tonix Pharmaceuticals to Present at 2024 BIO Convention

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company listed on Nasdaq under the symbol TNXP, has announced that its Chief Operating Officer, Jessica Morris, will present at the 2024 BIO International Convention. The event is scheduled to take place from June 3-6, 2024, in San Diego, California, and Morris's presentation is slated for June 4 at 10:45 a.m. PT at the San Diego Convention Center’s Theater 1. 

Tonix Pharmaceuticals is focused on developing therapies to treat and prevent human disease, particularly in the realm of central nervous system (CNS) disorders. The company is preparing to submit a New Drug Application (NDA) to the FDA in the latter half of 2024 for Tonmya™, a candidate drug intended for the management of fibromyalgia. The efficacy of Tonmya™ has been supported by two statistically significant Phase 3 studies.

The company’s development pipeline also includes TNX-102 SL, which is being investigated for the treatment of acute stress reaction and fibromyalgia-type Long COVID. Beyond fibromyalgia, Tonix's CNS portfolio features TNX-1300, a biologic aimed at treating cocaine intoxication. This particular drug has received a Breakthrough Therapy designation from the FDA.

In addition to CNS disorders, Tonix is also working on biologics for immunology applications, targeting conditions such as organ transplant rejection, autoimmunity, and cancer. One notable candidate is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154), designed to prevent allograft rejection and treat autoimmune diseases.

Tonix has a commercial subsidiary, Tonix Medicines, which currently markets two products for the treatment of acute migraines in adults: Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray). Both products are approved for use in managing acute migraines with or without aura.

The company makes it clear that its product development candidates, including Tonmya™, are investigational new drugs or biologics and have not yet received approval for any indication. The name Tonmya™ has been conditionally accepted by the FDA for TNX-102 SL specifically for managing fibromyalgia, although it remains unapproved.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!